



## FOR IMMEDIATE RELEASE

### **MTTI announces that response of colorectal cancer to treatment can be detected as early as one day after a single administration of drug**

**West Chester, Pa, Dec 1, 2016 (Business Wire)**---Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be detected with their innovative diagnostic agent (Tc-99m duramycin-**TumorVue™**) as early as one day after a single administration of drug. Results from this preclinical study were published online\*.

“Although imaging agents such as <sup>18</sup>F-FDG show great promise as biomarkers for early response to targeted cancer therapy, conflicting results are reported after immunotherapy. If our preclinical findings can be confirmed in patients, **TumorVue™** has the potential to fill this gap since it does not seem to be hampered by the presence or absence of an inflammatory response”, said Professor Sigrid Stroobants of the Antwerp University Hospital (**UZA**).

“Detection of early treatment response will allow for improved management of cancer patients in the clinic. This study demonstrated that **TumorVue™** enables readout of tumor response to targeted therapy as early as one day after start of treatment,” said Dr. Leonie wyffels at the University of Antwerp’s Molecular Imaging Center Antwerp (**UAntwerp-MICA**). “The superiority of **TumorVue™** over <sup>18</sup>F-FDG for early detection of treatment response in colorectal tumors is exciting.”

Chris Pak, President and CEO of MTTI said, “We are encouraged by the results of **TumorVue™** for detection of treatment response to targeted therapy as early as one day. Our goal is to translate these findings into patients to differentiate responders from non-responders. This innovative agent will be a powerful tool for personalized medicine where cancer patients will be spared the toxicity of ineffective therapy.”

**UAntwerp-MICA** was founded in 2010 as a joint effort by the **UAntwerp** and the **UZA** and has become one of the front runners in translational from bench to patient-molecular imaging research. **UAntwerp** is not an island: we build bridges to secondary education, to industry and, by extension, to society as a whole. With over 5,000 members of staff, UA is one of the most important employers in Antwerp, Flanders’ largest city. More information: [www.uantwerp.be](http://www.uantwerp.be)

**MTTI** is a privately held biotechnology company focused on the development of diagnostic technologies. More information: [www.mtarget.com](http://www.mtarget.com).

**Contact:** Chris Pak, Email: [cpak@mtarget.com](mailto:cpak@mtarget.com); Tel: (610) 738-7938;  
Peter Demeyer, Email: [peter.demeyer@uantwerpen.be](mailto:peter.demeyer@uantwerpen.be)

###

\*J Nucl Med. 2016 as doi:10.2967/jnumed.116.182014. 99mTc-duramycin SPECT imaging of early tumor response to targeted therapy: a comparison with 18F-FDG PET.